CONFRONTING PICTURE OF GROWING WOMEN’S HEALTH CRISIS IN UTERINE CANCERS. ANZGOG State of the Nation report highlights inequities in uterine cancer outcomes across Australia
With
Associate Professor Yoland Antill, Director and Deputy Chair, Australia New Zealand Gynaecological Oncology Group (ANZGOG)
SEGMENT
Filmed in Melbourne | December 2025
Uterine cancers have become Australia’s fastest-growing women’s cancer, with incidence doubling over the past 25 years and projected to continue to surge. Without immediate action, more than 44,000 women are expected to be diagnosed by 2035, and 8,900 will lose their lives to the disease.
Released November 2025, Australia’s first State of the Nation: Uterine Cancers in Australia 2025 report by the Australia New Zealand Gynaecological Oncology Group (ANZGOG), reveals a confronting picture of a growing women’s health crisis that has gone largely unseen and one that now requires immediate, coordinated national action.
Once considered a cancer that primarily affected older women, the report highlights an alarming new trend: incidence is now rising fastest among women aged 25 to 44, with cases in this age group expected to increase by around 60 per cent alone, over the next decade.
Despite its growing impact, uterine cancer remains largely invisible in Australia’s cancer conversation. The limited research available notes, 94 per cent of women are unaware of what uterine or endometrial cancers are yet increased awareness of the disease and risk factors could prevent up to 60 per cent of future diagnoses. Research investment for uterine cancers lags far behind other cancers.
In addition, support and psychosocial care for women living with uterine cancers are inconsistent, and currently there is no dedicated national advocacy organisation. Many women face pain, fatigue, anxiety and long-term side effects alone.
State of the Nation report sets out a national plan to reverse the rise in uterine cancers and transform outcomes for Australian women
The report identifies five urgent priorities: halve incidence, eliminate inequities, ensure access to precision care, support every woman to live well, and invest in research and data. Achieving these goals will require united action from government, researchers, clinicians, industry and the community to deliver the innovation, equity and support Australian women deserve.
Source: Adapted from ANZGOG media release November 2025
Report: ANZGOG State of the Nation Report into Uterine Cancers can be read here https://www.anzgog.org.au/sotn-uterine-cancer, prepared by Insight Economics
-
Trends report identifies prototyping targets for breakthroughs in digital and hybrid futures
Vishaal Kishore, a Professor of Innovation and Public Policy at RMIT in Melbourne, serves as the Executive Chair of the RMIT-Cisco Health Transformation Lab and RMIT’s Director of Impact. Led by the RMIT-Cisco Health Transformation Lab, the National Industry Innovation Network (NIIN) Health Alliance combines the best minds, technologists, industry capabilities and academic resources to solve pressing industry and social challenges through technology-driven innovation. The NIIN aims to pool insights and expertise to address national health challenges, marking its first vertical focus on health.
-
Care workforce challenges
In a wide ranging report looking at the carer needs across Australia, PwC Australia published Reimagine Care Workforce Solutions in October 2022.
Australian Health Journal spoke with Kerryn Dillon, Director Ageing and Reablement and Health Workforce at PwC Australia about the community care sectors of aged care, disability care and childcare the report covers.
-
Report gives insights to clinical trial activity in Australia
Established in 2024, Bellberry is a Adelaide-based national, not-for-profit organisation that provides streamlined scientific and ethical reviews of human research. It is the 2025 winner of the Championing Health Award in the Telstra Best of Business Awards.
Australian Health Journal spoke with Bellberry Limited CEO, Kylie Sproston on the organisation and the findings in activity documented in the Clinical Trial Activity Report (CTAR) 2024.
